Drug lymphocyte stimulation test is not useful for side effects of anti-tuberculosis drugs despite its timing

Area of Science:

• Pharmacology
• Immunology
• Clinical Medicine

Background:

• Adverse reactions to anti-tuberculosis drugs are a clinical concern.
• Previous studies indicated low sensitivity of drug lymphocyte stimulation testing (DLST) when performed during the first week of adverse reactions.
• The impact of the timing of DLST on its diagnostic utility remained unclear.

Purpose of the Study:

• To evaluate the optimal timing for performing DLST in patients experiencing adverse reactions to anti-tuberculosis drugs.
• To compare the sensitivity of DLST performed at different time points after the onset of adverse reactions.

Main Methods:

• Patients with adverse reactions (rash, hepatitis, fever) to anti-tuberculosis drugs underwent initial DLST within the first week.
• Participants were randomized into two groups for a second DLST: Group A at 2 months and Group B at >12 months post-reaction.
• Causative drugs were identified using oral drug provocation tests.

Main Results:

• The sensitivity of DLST performed in the first week was low at 14.3%.
• DLST sensitivity in Group A (2 months post-reaction) was 5.0%.
• DLST sensitivity in Group B (>12 months post-reaction) was 6.7%.

Conclusions:

• DLST is not a useful diagnostic tool for identifying causative drugs in patients with rash, hepatitis, or fever reactions to anti-tuberculosis medications.
• The timing of DLST performance does not significantly improve its diagnostic accuracy for these adverse drug reactions.